Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Calaspargase pegol-mknl + Dexamethasone + Etoposide + Ifosfamide + Methotrexate |
Synonyms | mSMILE |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Calaspargase pegol-mknl | Asparlas | CALASP|EZN-2285EZN 2285|EZN2285|SC-PEG E. coli L-asparaginase | Asparlas (calaspargase pegol-mknl) is a pegylated version of L-asparaginase derived from E.coli, which converts L-asparagine to ammonia and L-aspartic acid, potentially resulting in reduced levels of asparagine leading to inhibition of protein synthesis and tumor cell proliferation, and increased cell death (NCI Drug Dictionary). Asparlas (calaspargase pegol-mknl) is approved as a component of multi-agent chemotherapy in acute lymphoblastic leukemia (FDA.gov). | |
Dexamethasone | Adexone | Desametasone | ||
Etoposide | Vepesid | EPEG|Eposin|VP-16|VP-16-213 | TOPO2 inhibitor 5 | Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary). |
Ifosfamide | Cyfos | Z4942 | Chemotherapy - Alkylating 18 | Cyfos (ifosfamide) is an alkylating agent, which cross-links DNA, thereby inhibiting DNA replication (NCI Drug Dictionary). |
Methotrexate | Abitrexate | Amethopterin | Chemotherapy - Antimetabolite 14 | Methotrexate is an antimetabolite, which inhibits DHFR resulting in decreased immune function and antineoplastic activity and is FDA approved for psoriasis, RA, and several cancers including choriocarcinoma, AML, lung, head and neck and epidermoid (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03719105 | Phase I | Pembrolizumab Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Pralatrexate + Prednisone Calaspargase pegol-mknl + Dexamethasone + Etoposide + Ifosfamide + Methotrexate | Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | Recruiting | USA | 0 |